Vir Biotechnology

Yahoo Finance • 2 days ago

Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000

Key Points 72,559 shares were sold for a total transaction value of ~$664,000 on April 6, 2026. This sale represented 6.76% of De Backer's total holdings at the time of the transaction. The transaction involved only direct holdings, with... Full story

Yahoo Finance • 4 days ago

Vir Biotechnology (VIR) Leading with Its BiTEs Therapy

Jacob Funds, a mutual fund company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Fund started the year optimistically, expecting fiscal and monetary policies to boost an economy showing... Full story

Yahoo Finance • 2 months ago

TheStreet Pro: Four Stocks that Will Win Despite “Irrational Panic” over AI

The big news this week is AI may not be the economic savior that companies were hoping for. Sure, AI will help cut costs and make companies more profitable. At least, initially. What happens next is the big question. Claim 50% Off TipRank... Full story

Yahoo Finance • 2 months ago

Vir Biotechnology launches $200M public stock offering

* Vir Biotechnology (VIR [https://seekingalpha.com/symbol/VIR]) announced [https://seekingalpha.com/pr/20412007-vir-biotechnology-announces-proposed-public-offering-of-common-stock] plans to offer $200M of its common stock in an underwri... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest moves midday: IBM, AMD, Dillard's, Novo Nordisk, Keysight Technologies & more

Check out the companies making headlines in midday trading: Dillard's — Shares fell 7% after the department store posted weaker-than-expected revenue in the holiday quarter. Fourth-quarter revenue came in at $1.99 billion, while analysts p... Full story

Yahoo Finance • 2 months ago

Anthropic expands Claude AI chatbot, Keurig Dr Pepper's Q4 beat

Market Catalysts Host Julie Hyman and Yahoo Finance Markets and Data Editor Jared Blikre tracks several of the day's top trending stock tickers, including Anthropic (ANTH.PVT) announcing new tools for its Claude AI chatbot, Keurig Dr Peppe... Full story

Yahoo Finance • 2 months ago

Vir Biotech Catapults On Its $1.71 Billion Deal With Astellas

Vir stock catapulted Tuesday after the small biotech company smashed fourth-quarter sales views and signed a deal with Astellas Pharma. Continue Reading... Full story

Yahoo Finance • 2 months ago

Vir Biotechnology (VIR) Earnings Call Transcript

Image source: The Motley Fool. DATE Monday, Feb. 23, 2026 at 5:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Dr. Marianne De BackerChief Medical Officer — Dr. Mark D. EisnerChief Financial Officer — Jason O’ByrneConsulting Cli... Full story

Yahoo Finance • 4 months ago

Vir Biotechnology issues license to Norgine to market hepatitis D candidate

[Hepatitis Concept] eenevski/iStock via Getty Images * Vir Biotechnology (VIR [https://seekingalpha.com/symbol/VIR]) has granted Norgine Pharma UK an exclusive license to market its experimental chronic hepatitis d treatment, a combinat... Full story

Yahoo Finance • 4 months ago

Is Alnylam Pharmaceuticals a Millionaire Maker?

Key Points Alnylam has been a big winner for investors since its IPO in 2004. The drugmaker's future looks promising. Whether or not Alnylam is a millionaire maker, the stock should be able to generate exceptional long-term returns.10 sto... Full story

Yahoo Finance • 5 months ago

Ability Biotherapeutics Expands its Scientific Advisory Board with the Appointment of Dr. John Burke and Dr. Alan Korman

MONTREAL, November 19, 2025--(BUSINESS WIRE)--Ability Biotherapeutics, a next-generation biotherapeutics company developing logic-gated antibodies for safer and more effective immunotherapies, announces the appointment of Dr. John Burke an... Full story

Yahoo Finance • 5 months ago

Vir Biotechnology outlines accelerated hepatitis delta milestones and cash runway into mid-2027 as ECLIPSE 1 completes enrollment early

Earnings Call Insights: Vir Biotechnology, Inc. (VIR) Q3 2025 MANAGEMENT VIEW * CEO Marianne De Backer highlighted the completion of enrollment in ECLIPSE 1, Vir’s first registrational Phase III study for hepatitis delta, ahead of inte... Full story

Yahoo Finance • 7 months ago

Stocks making the biggest moves midday: Alphabet, Bruker, Sprinklr, Dollar Tree & more

Check out the companies making the biggest moves midday: Bruker – The diagnostics solutions stock dropped more than 11% after it announce the sale of $600 million in convertible stocks. The decline puts Bruker on pace for its biggest one-d... Full story

Yahoo Finance • 7 months ago

Stocks making the biggest moves premarket: Alphabet, Macy's, Dollar Tree, Six Flags and more

Check out the companies making headlines in premarket trading. Alphabet — The parent of Google and YouTube jumped more than 6% after a federal judge ruled that Alphabet can keep its Chrome browser. But Google won't be able to sign exclusiv... Full story

Yahoo Finance • 8 months ago

Vir Biotech enrolls first patient in hepatitis delta virus trial

SAN FRANCISCO - Vir Biotechnology, Inc. (NASDAQ:VIR), currently trading at $5.24 and identified as undervalued by InvestingPro models, announced Thursday the enrollment of the first participant in its ECLIPSE 2 Phase 3 clinical trial, eval... Full story

Yahoo Finance • 9 months ago

Vir Biotechnology EVP Eisner sells $57k in stock

Mark Eisner, Executive Vice President and Chief Medical Officer at Vir Biotechnology (NASDAQ:VIR), sold a total of 10,382 shares of common stock in two transactions, according to a recent Form 4 filing. The sale comes as the biotech compan... Full story

Yahoo Finance • 3 years ago

Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference

SAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Vir’s Executive Vice President, Chief Medical Officer and Interim Head of Research, is participating in a... Full story

Yahoo Finance • 3 years ago

Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023

SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new data from its chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) clinical programs have... Full story

Yahoo Finance • 3 years ago

Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023

SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2... Full story

Yahoo Finance • 3 years ago

Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats

– New investment of approximately $50 million from Biomedical Advanced Research and Development Authorityincludes $40 million in Project NextGen funds – – Contract expands existing support for the development of candidates for prevention... Full story